Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Is it time to REWIND the cardiorenal clock in diabetes?

Verma S, Mazer CD, Perkovic V.

Lancet. 2019 Jun 7. pii: S0140-6736(19)31267-X. doi: 10.1016/S0140-6736(19)31267-X. [Epub ahead of print] No abstract available.

PMID:
31189510
2.

Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes.

Ohkuma T, Jun M, Chalmers J, Cooper ME, Hamet P, Harrap S, Zoungas S, Perkovic V, Woodward M; ADVANCE Collaborative Group.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):862-872. doi: 10.2215/CJN.13391118. Epub 2019 Jun 3.

PMID:
31160317
3.

Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Cheung AK, Chang TI, Cushman WC, Furth SL, Ix JH, Pecoits-Filho R, Perkovic V, Sarnak MJ, Tobe SW, Tomson CRV, Cheung M, Wheeler DC, Winkelmayer WC, Mann JFE; Conference Participants.

Kidney Int. 2019 May;95(5):1027-1036. doi: 10.1016/j.kint.2018.12.025.

PMID:
31010478
4.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
5.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

PMID:
30990260
6.

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.

Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.

PMID:
30882240
7.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.

Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B.

Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.

8.

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.

Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.

PLoS One. 2019 Mar 7;14(3):e0213192. doi: 10.1371/journal.pone.0213192. eCollection 2019.

9.

Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial.

Garg AX, Chan MTV, Cuerden MS, Devereaux PJ, Abbasi SH, Hildebrand A, Lamontagne F, Lamy A, Noiseux N, Parikh CR, Perkovic V, Quantz M, Rochon A, Royse A, Sessler DI, Shah PJ, Sontrop JM, Tagarakis GI, Teoh KH, Vincent J, Walsh M, Yared JP, Yusuf S, Whitlock RP; SIRS Investigators.

CMAJ. 2019 Mar 4;191(9):E247-E256. doi: 10.1503/cmaj.181644.

10.

Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol.

Smyth B, Krishnan AV, Gallagher M, Kiernan M, Snelling P, Hawley C, Fernando M, Hand S, Grimley K, Burman J, Heath A, Kang A, Perkovic V, Jardine MJ.

BMJ Open. 2019 Jan 15;9(1):e023736. doi: 10.1136/bmjopen-2018-023736.

11.

Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial.

Gray NA, Zuo L, Hong D, Smyth B, Jun M, De Zoysa J, Vo K, Howard K, Wang J, Lu C, Liu Z, Cass A, Perkovic V, Jardine M.

Nephrology (Carlton). 2019 Feb 5. doi: 10.1111/nep.13530. [Epub ahead of print]

PMID:
30723975
12.

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V.

Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4.

PMID:
30697905
13.

Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology.

Okpechi IG, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Levin A, Lunney M, Olanrewaju TO, Perkovic V, Perl J, Rashid HU, Rondeau E, Salako BL, Samimi A, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, Bello AK.

Kidney Int Suppl (2011). 2018 Feb;8(2):82-89. doi: 10.1016/j.kisu.2017.10.012. Epub 2018 Jan 19. Review.

14.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.

PMID:
30635299
15.

Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial.

Jardine MJ, Li N, Ninomiya T, Feng X, Zhang J, Shi J, Zhang Y, Zhang R, Zhang J, Hao J, Perkovic V, Heerspink HL, Wu Y, Yan LL, Neal B.

J Ren Nutr. 2018 Dec 24. pii: S1051-2276(18)30247-4. doi: 10.1053/j.jrn.2018.10.009. [Epub ahead of print]

PMID:
30591358
16.

Canagliflozin and Stroke in Type 2 Diabetes Mellitus.

Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B.

Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009.

17.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
18.

Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.

Ohkuma T, Jun M, Rodgers A, Cooper ME, Glasziou P, Hamet P, Harrap S, Mancia G, Marre M, Neal B, Perkovic V, Poulter N, Williams B, Zoungas S, Chalmers J, Woodward M; ADVANCE Collaborative Group.

Hypertension. 2019 Jan;73(1):84-91. doi: 10.1161/HYPERTENSIONAHA.118.12060.

19.

New hypoglycemic agents and the kidney: what do the major trials tell us?

Smyth B, Perkovic V.

F1000Res. 2018 Nov 23;7. pii: F1000 Faculty Rev-1844. doi: 10.12688/f1000research.16135.1. eCollection 2018. Review.

20.

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.

Cooper ME, Perkovic V, Groop PH, Hocher B, Hehnke U, Meinicke T, Koitka-Weber A, van der Walt S, von Eynatten M.

J Hypertens. 2019 Jun;37(6):1294-1300. doi: 10.1097/HJH.0000000000002032.

PMID:
30540657
21.

Reducing cardiovascular risk in people with diabetes and kidney disease.

Neuen BL, Perkovic V.

Med J Aust. 2018 Nov 19;209(10):438-439. No abstract available.

PMID:
30428818
22.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

PMID:
30418475
23.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
24.

ACCORDION: Ensuring That We Hear the Music Clearly.

Wong MG, Heerspink HJL, Perkovic V.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1621-1623. doi: 10.2215/CJN.11370918. Epub 2018 Oct 25. No abstract available.

PMID:
30361334
25.

Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop.

Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, Tugwell P, Pecoits-Filho R, Crowe S, Harris T, Van Biesen W, Winkelmayer WC, Levin A, Thompson A, Perkovic V, Ju A, Gutman T, Bernier-Jean A, Viecelli AK, O'Lone E, Shen J, Josephson MA, Cho Y, Johnson DW, Sautenet B, Tonelli M, Craig JC; SONG Implementation Workshop Investigators.

Kidney Int. 2018 Dec;94(6):1053-1068. doi: 10.1016/j.kint.2018.08.018. Epub 2018 Oct 22.

PMID:
30360959
26.

Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist".

Matthews DR, Perkovic V, Mahaffey KW.

Circulation. 2018 Aug 7;138(6):660-661. doi: 10.1161/CIRCULATIONAHA.118.035717. No abstract available.

PMID:
30354619
27.

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.

Heerspink HJL, List J, Perkovic V.

Diabetes Obes Metab. 2018 Oct;20 Suppl 3:14-18. doi: 10.1111/dom.13417. Review.

28.

Glucose lowering and the kidney: are all drug classes equal?

Wong MG, Jardine M, Perkovic V.

Lancet Diabetes Endocrinol. 2018 Nov;6(11):835-837. doi: 10.1016/S2213-8587(18)30291-2. Epub 2018 Oct 3. No abstract available.

PMID:
30292590
29.

Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S.

Cochrane Database Syst Rev. 2018 Sep 24;9:CD011798. doi: 10.1002/14651858.CD011798.pub2. Review.

PMID:
30246878
30.

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V.

Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.

31.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B.

Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.

32.

Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform.

Heerspink HJL, Perkovic V.

Clin J Am Soc Nephrol. 2018 Jun 7;13(6):946-948. doi: 10.2215/CJN.01290118. Epub 2018 Apr 26. No abstract available.

33.

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.

Rådholm K, Wu JH, Wong MG, Foote C, Fulcher G, Mahaffey KW, Perkovic V, Neal B.

Diabetes Res Clin Pract. 2018 Jun;140:118-128. doi: 10.1016/j.diabres.2018.03.027. Epub 2018 Mar 28. Review.

34.

Baseline characteristics and enrichment results from the SONAR trial.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Aug;20(8):1829-1835. doi: 10.1111/dom.13315. Epub 2018 May 1.

35.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA® investigators.

Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3.

36.

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus.

Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B.

Circulation. 2018 Jul 31;138(5):458-468. doi: 10.1161/CIRCULATIONAHA.118.034222.

37.

Effect of extended hours dialysis on sleep quality in a randomized trial.

Liao JL, van den Broek-Best O, Smyth B, Hong D, Vo K, Zuo L, Gray NA, Chan CT, de Zoysa J, Perkovic V, Jiang L, Jardine M.

Nephrology (Carlton). 2019 Apr;24(4):430-437. doi: 10.1111/nep.13236.

PMID:
29424935
38.

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9.

39.

Associations between body mass index and the risk of renal events in patients with type 2 diabetes.

Mohammedi K, Chalmers J, Herrington W, Li Q, Mancia G, Marre M, Poulter N, Rodgers A, Williams B, Perkovic V, Coresh J, Woodward M.

Nutr Diabetes. 2018 Jan 17;8(1):7. doi: 10.1038/s41387-017-0012-y.

40.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

41.

Chronic kidney disease and the global NCDs agenda.

Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V.

BMJ Glob Health. 2017 Jul 6;2(2):e000380. doi: 10.1136/bmjgh-2017-000380. eCollection 2017. No abstract available.

42.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Neal B, Perkovic V, Matthews DR.

N Engl J Med. 2017 Nov 23;377(21):2099. doi: 10.1056/NEJMc1712572. No abstract available.

43.

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group.

Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.

44.

Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON.

Jun M, Ohkuma T, Zoungas S, Colagiuri S, Mancia G, Marre M, Matthews D, Poulter N, Williams B, Rodgers A, Perkovic V, Chalmers J, Woodward M; ADVANCE Collaborative Group.

Diabetes Care. 2018 Jan;41(1):163-170. doi: 10.2337/dc17-1467. Epub 2017 Oct 27.

PMID:
29079715
45.

Action plan for optimizing the design of clinical trials in chronic kidney disease.

Perkovic V, Craig JC, Chailimpamontree W, Fox CS, Garcia-Garcia G, Benghanem Gharbi M, Jardine MJ, Okpechi IG, Pannu N, Stengel B, Tuttle KR, Uhlig K, Levey AS.

Kidney Int Suppl (2011). 2017 Oct;7(2):138-144. doi: 10.1016/j.kisu.2017.07.009. Epub 2017 Sep 20. Review.

46.

Closing the gap between evidence and practice in chronic kidney disease.

Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S, Chailimpamontree W, Craig JC, O'Donoghue DJ, Perkovic V, Powe NR, Roberts CJ, Suzuki Y, Tanaka T, Uhlig K.

Kidney Int Suppl (2011). 2017 Oct;7(2):114-121. doi: 10.1016/j.kisu.2017.07.006. Epub 2017 Sep 20. Review.

47.

Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.

Ren S, Wang Y, Xian L, Toyama T, Jardine M, Li G, Perkovic V, Hong D.

PLoS One. 2017 Sep 12;12(9):e0184398. doi: 10.1371/journal.pone.0184398. eCollection 2017.

48.

Are SGLT2 Inhibitors Ready for Prime Time for CKD?

Pecoits-Filho R, Perkovic V.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):318-320. doi: 10.2215/CJN.07680717. Epub 2017 Sep 11. No abstract available.

49.

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.

Webb DJ, Coll B, Heerspink HJL, Andress D, Pritchett Y, Brennan JJ, Houser M, Correa-Rotter R, Kohan D, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Busch R, Pergola P, Parving HH, de Zeeuw D.

Drugs R D. 2017 Sep;17(3):441-448. doi: 10.1007/s40268-017-0201-0.

50.

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Marx N, McGuire DK, Perkovic V, Woerle HJ, Broedl UC, von Eynatten M, George JT, Rosenstock J.

Diabetes Care. 2017 Sep;40(9):1144-1151. doi: 10.2337/dc17-0068.

PMID:
28830955

Supplemental Content

Loading ...
Support Center